Vinpocetine - instructions for use, dose, side effects, contraindications

Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; enhances the transport of glucose to the brain, through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca ²⁺ - dependent phosphodiesterase; increases the levels of adenosine monophosphate (AMP), cyclic guanosine monophosphate (cGMP) and adenosine triphosphate (ATP) of the brain. Increases the exchange of norepinephrine and serotonin of the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the return of oxygen in the erythrocytes. Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the indices of the systemic circulation. Does not have the effect of "stealing" and enhances blood supply, especially in ischemic areas of the brain. Penetrates through the placental barrier

Pharmacokinetics:

Quickly absorbed. Time to reach the maximum concentration in the blood plasma 1 hour. Absorption occurs mainly in the proximal parts of the gastrointestinal tract. When passing through the wall of the intestine is not exposed to metabolism. The maximum concentration in tissues is noted after 2-4 hours after ingestion.The connection with proteins is 66%, the bioavailability with ingestion is 7%. Clearance 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism. At repeated receptions the kinetics has linear character. The half-life in humans is 4.83 ± 1.29 hours. It is excreted by the kidneys and through the intestine in the ratio 3: 2.

Indications:

- reduction of neurological and psychiatric symptoms in various forms of cerebral circulatory insufficiency (including the reducing step ischemic or hemorrhagic stroke, the consequences of stroke, transient ischemic attack, vascular dementia; vertebrobasilar insufficiency, cerebral atherosclerosis, traumatic and hypertensive encephalopathy);

- chronic vascular diseases of the choroid and retina;

- perceptual hearing loss, Meniere's disease, idiopathic tinnitus.

Contraindications:

- acute phase of hemorrhagic stroke, severe ischemic heart disease, severe arrhythmias, hypersensitivity to any of the components of the drug;

- intolerance to galactose, lactase deficiency or malabsorption of glucose-galactose;

- pregnancy (possibly placental bleeding and spontaneous abortion, probably as a result of increased placental blood supply);

- lactation period (when using the drug, it is necessary to stop breastfeeding);

- children under 18 years (due to insufficient data).

Dosing and Administration:

Inside, after eating, 1 tablet 3 times a day. The initial daily dose is 15 mg. The maximum daily dose is 30 mg. Duration of treatment to 3 months. In diseases of the kidneys or liver, the drug is prescribed in the usual dose.

Side effects:

From the cardiovascular system: ECG change (segment depression ST, interval lengthening QT), tachycardia, extrasystole, lability of blood pressure, sensation of hot flashes.

From the central nervous system: sleep disturbances (insomnia or increased drowsiness), dizziness, headache.

On the part of the digestive system: dry mouth, nausea, heartburn.

Others: allergic reactions, general weakness, increased sweating.

Overdose:

Symptoms: increased severity of side effects.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Interactions are not observed when applied simultaneously with β-blockers (chloranolol, pindolol), clopamid, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide, imipramine.

The simultaneous use of vinpocetine and methyldopa sometimes caused some strengthening of the hypotensive effect, so this treatment requires regular monitoring of blood pressure.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently administering with the drugs central, antiarrhythmic and anticoagulant action. Increases the risk of hemorrhagic complications against heparin therapy.

Special instructions:

Presence of the syndrome of the prolonged interval QT and taking medications that cause lengthening of the interval QT, requires periodic ECG monitoring. In case of lactose intolerance, it should be taken into account that one tablet contains about 225 mg of lactose.Data on the effect of vinpocetine on the ability to drive a car and perform work that requires speed of psychomotor reactions is not.

Form release / dosage:

Tablets 5 mg.

Packaging:

10 tablets in a blister (PVC / Aluminum). 1, 2, 3, 4, 5 blisters with instruction on medical application.

Storage conditions:

List B. In a dry place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:3 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N014184 / 01

Date of registration:18.09.2008

The owner of the registration certificate:SHREYA LIFE SENENSIZ Pvt.Ltd. SHREYA LIFE SENENSIZ Pvt.Ltd. India

Manufacturer: & nbsp

Shraya Life Senses Pvt. Ltd. India

Representation: & nbspSHREYA LIFE SENENSIZ Pvt.Ltd. SHREYA LIFE SENENSIZ Pvt.Ltd. India

Information update date: & nbsp11.10.15

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)